Structure Therapeutics files Form 3 for CCO

Structure Therapeutics Inc. submitted a Form 3 for insider John Joseph Berrios, who serves as Chief Commercial Officer.

Rhea-AI Filing Summary

Structure Therapeutics Inc. submitted a Form 3 for insider John Joseph Berrios, who serves as Chief Commercial Officer.

The report shows no buy, sell, or other equity transactions, no derivative transactions, and no holdings reported for him as of this initial statement.

Key Figures

Reported buy transactions: 0 transactions Reported sell transactions: 0 transactions Derivative transactions: 0 transactions +1 more

4 metrics

Reported buy transactions 0 transactions Buy transaction count in Form 3 transaction summary

Reported sell transactions 0 transactions Sell transaction count in Form 3 transaction summary

Derivative transactions 0 transactions Derivative transaction count in Form 3 transaction summary

Holding entries 0 holdings Number of holdings reported for the insider in this Form 3

Key Terms

Form 3, Chief Commercial Officer, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Commercial Officer financial

"officer_title": "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

reporting person regulatory

""reportingPersons": [{ "name": "Berrios John Joseph""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for Structure Therapeutics (GPCR) report about John Joseph Berrios?

It identifies John Joseph Berrios as Chief Commercial Officer of Structure Therapeutics Inc. and lists him as the reporting person, with no equity transactions, derivative transactions, or holdings reported in this initial Form 3.

Does the GPCR Form 3 show any stock purchases or sales by John Joseph Berrios?

No. The Form 3 transaction summary shows 0 buy transactions and 0 sell transactions, and the transactions list is empty, indicating no reported purchases or sales of Structure Therapeutics Inc. securities for this insider.

Are any derivative securities reported for John Joseph Berrios in Structure Therapeutics (GPCR) Form 3?

No derivative securities are reported. The derivative section is empty and the summary shows 0 derivative transactions, indicating no options, warrants, or other derivative positions are listed for him in this Form 3.

What insider role does John Joseph Berrios hold at Structure Therapeutics (GPCR)?

John Joseph Berrios is reported as an officer with the title Chief Commercial Officer. He is not marked as a director or a ten percent owner, making him an executive officer reporting person for Structure Therapeutics Inc.

Does the Structure Therapeutics (GPCR) Form 3 indicate any holdings for John Joseph Berrios?

No holdings are indicated. The structured data show 0 holding entries and an empty transactions list, so this initial Form 3 reports no beneficial ownership positions for John Joseph Berrios in the issuer’s securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/07/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Berrios John Joseph

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jun Yoon, Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)